Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hal Mintz And Sabby Capital Disclose New Investments In StemCells Inc (STEM) And Skystar Bio-Pharmaceutical Company (SKBI)

Hal Mintz, the manager of Sabby Capital, believes StemCells Inc (NASDAQ:STEM) is a good investment and has opened a position for his fund. According a recent filing with the Securities and Exchange Commission, Sabby Capital has acquired 6.85 million shares, which account for approximately 9.98% of the total number of shares outstanding.

StemCells Inc (NASDAQ:STEM)

Ken Griffin, the billionaire hedge fund manager, also likes StemCells Inc (NASDAQ:STEM) and has increased his fund’s stake in the company by 133% during the first quarter of this year. In its latest 13F filing, Citadel has reported ownership of approximately 25,500 shares. David E. Shaw, on the other hand, has chosen to reduce his fund’s investment in this stock by a half to 21,600 shares. Joseph Edelman, the manager of Perceptive Advisors, is also keeping tabs on StemCells Inc (NASDAQ:STEM) having made no changes to their investment during the first quarter. Perceptive Advisors holds a little more than 271,000 shares.

Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) is another new addition to the equity portfolio of Sabby Capital. Mintz has bought approximately 858,500 shares, which gives him and Sabby Capital control over 9.99% of the total number of shares outstanding.

None of the hedge funds that we track currently holds a position in Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI). For the first quarter of 2014, the company posted revenues of $6.83 million, up 23% year-over-year, and earnings per share (EPS) of $0.13.  So far this year the stock has been trending upwards and has advanced 52% to a current price of $5.31 per share. This gives the company a market cap of $40.4 million. The stock is traded at a trailing Price to Earnings of 3.xx, which is significantly lower than the industry average of 21.60.

Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) recently announced an agreement with a dedicated institutional investor to acquire $5 million worth of registered securities. The proceedings are to be used by Skystar for corporate purposes and research and development.

Disclosure: none.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!